Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Basal Cell 8Medulloblastoma 6Recurrence 4Skin Neoplasms 3Basal Cell Nevus Syndrome 3Thrombocythemia, Essential 2Prostatic Neoplasms 2Primary Myelofibrosis 2Polycythemia Vera 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Glioma 2Glioblastoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Astrocytoma 2Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Pancreatic Ductal Adenocarcinoma 1Pancreatic Diseases 1

Interventions

Vincristine 25Cyclophosphamide 25Irinotecan 21Temozolomide 18Doxorubicin 16Radiotherapy 15Filgrastim 15Ifosfamide 14Dactinomycin 14Etoposide 11Vinorelbine 9Melphalan 9Magnetic Resonance Spectroscopy 9Granulocyte Colony-Stimulating Factor 9Radiation 8pegfilgrastim 7X-Rays 7Specimen Handling 7Sirolimus 7Topotecan 6Phantoms, Imaging 6Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6cixutumumab 5Busulfan 5Biopsy 5temsirolimus 4irinotecan sucrosofate 4fludarabine 4etoposide phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rhabdomyosarcoma × sonidegib × Clear all
NCT01125800 2017-03-20

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Novartis

Phase 1/2 Completed
76 enrolled 18 charts
CNSGastrointestinalSarcoma

Astrocytoma, Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡